© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of Epothilone A starts deep in the soil of southern Africa. Researchers in the 1980s collected samples of Sorangium cellulosum, a rare myxobacterium, from a riverbed in Zambia. This organism became more than a footnote when scientists uncovered its potent anticancer properties a decade later. Fast forward to the late 1990s, this natural product began to pull serious attention away from paclitaxel, also known as Taxol, the reigning star among microtubule inhibitors. Anyone who’s ever tried to keep a scientific breakthrough secret knows it doesn’t last long; labs in Europe and the United States raced to confirm epothilone’s prowess in destabilizing cancer cells. By the turn of the millennium, the story of Epothilone A had shifted from underground obscurity to front-line cancer research labs and biotech companies eager to find a drug that could outperform—and out-solve—Taxol’s issues with drug resistance.
Epothilone A shook up natural product chemistry, breaking into a crowded field of chemotherapies by doing what its peers struggled to accomplish. It targets the cell’s microtubule structure—think of these as railroad tracks guiding everything from cell division to movement. Because of its structure, Epothilone A makes dividing cancer cells trip over their own process, blocking the progression of the disease. Medicines based on this molecule don’t face the same headaches with multidrug resistance, especially where cancer cells pump out chemotherapy drugs, leading to treatment failure. It earned its reputation among oncologists and pharmacologists for staying effective where other treatments faltered.
Epothilone A presents itself as a yellowish, crystalline solid that barely dissolves in water—no surprise, considering its macrolide backbone. The molecule packs a 16-membered lactone ring with multiple chiral centers, making synthetic chemistry students sweat over each stereocenter. Its molecular formula reads C27H41NO6, weighing in at 475.62 g/mol. The boiling point sits high, reflecting the molecule’s complex framework. Only a handful of solvents coax it into solution; DMSO and ethanol do the trick for most lab applications. Its rigid backbone combined with a flexible side chain gives this molecule the ability to bind tightly and specifically to microtubules in target cells.
The pharmaceutical industry categorizes Epothilone A with rigorous standards. Quality material must show purity higher than 98% by HPLC, and containers need to be amber glass to protect against photodegradation, since UV light can tear apart the delicate lactone ring. Temperature during storage must stay between 2 and 8°C. Labels include the compound’s systematic name, concentration—most stock solutions follow a 1 mg/mL guideline in DMSO—and a warning that it’s strictly for research or API synthesis, not for human consumption unless further purified and approved.
The preparation challenge drew generations of organic chemists into a years-long race. The natural fermentation route may look romantic, but large-scale synthesis depends on semi-synthetic tweaks to microbial cultures or total synthesis using modular chemistry. Most labs kick off with advanced polyketide fragments, extending and linking each chain using aldol additions, Wittig reactions, and macrolactonization to close the hallmark ring. Every step brings its own pitfalls. Early routes produced only milligrams at a time; only with robust fermentation, clever feeding of precursor molecules or highly optimized total syntheses could researchers finally pump out grams to kilograms.
Epothilone A’s core structure allows for all sorts of chemical modifications. Tweaking the side chains or introducing halogens opens avenues for analogues that promise improved solubility or lower toxicity. Researchers built whole libraries by hydrogenating, oxidizing, or replacing functional groups, leading to molecules like Epothilone B and the clinically successful Ixabepilone. The ring’s ester linkage sometimes invites hydrolysis, which chemists counter by making amide bonds or swapping out sensitive atoms. Each variation gets run through assays to check its impact on microtubule inhibition and cytotoxicity in cancer cell lines.
Over time, Epothilone A collected an impressive roster of aliases. Scientists in the field sometimes use the shorthand “EpoA.” In the early literature, one finds mentions of F0128-A. In clinical circles, discussions frequently swirl around analogues—Epothilone B, Epothilone D (KOS-862), and Ixabepilone, which the FDA approved for cancer treatment. It matters to separate these not just by name, but by their subtle tweaks in structure and function. Brand names don’t generally apply to Epothilone A itself on the commercial drug market, but its descendants have found their way into trials under development codes and trade designations.
Anyone handling Epothilone A in a lab follows strict protocols. This compound disrupts eukaryotic cell division, so lab workers wear gloves, goggles, and lab coats to prevent accidental absorption. Fume hoods remain standard because of the risk of inhalation with powders or solutions. Disposal, as with most research chemicals, goes through regulated hazardous waste streams—lots of paperwork and triple containment. Good documentation tracks every milligram, ensuring traceability and compliance with safety officers' demands. Each batch ships with safety data sheets outlining risks, and dry powder gets reconstituted only under low-light conditions to avoid photodegradation.
Cancer therapy draws the majority of attention, and for good reason. Epothilone A and its analogues go to work in breast, ovarian, lung, and pancreatic cancers, often where standard options have stopped working. Medical research leans hard on these molecules as tools to understand microtubule dynamics. Some labs even explore potential uses in neurodegenerative disease, where stabilizing microtubules could stave off nerve cell decay. Beyond medicine, academic researchers turn to Epothilone A as a precision probe for dissecting cell biology, genetics, and biochemistry of mitosis and apoptosis. Its reach spans clinical, preclinical, and basic research settings in pharmaceutical science, oncology, and cell biology departments around the world.
Research into Epothilone A keeps accelerating. Clinics benefit from analogues that prove effective when paclitaxel fails, particularly among patients whose tumors became drug-resistant. Universities and biotech firms pour resources into figuring out which modifications to the core structure limit toxicity while boosting potency. Several pharma companies pushed derivatives to various phases of clinical trials; Ixabepilone even gained FDA approval for metastatic breast cancer. Academic teams tackle computational modeling, seeking analogues with greater selectivity for tumor cells over healthy tissue. Research grants fuel dozens of projects ranging from nanotechnology delivery systems to dual-action drugs that pair micelle formulations with targeting peptides. The field moves with urgency, given the stakes for patients who exhaust front-line therapies.
Keeping Epothilone A effective without crossing the line into unacceptable toxicity remains a chief concern. Typical studies focus on side effects like neuropathy, bone marrow suppression, and immunosuppression. Animal models highlight the margin between killing tumor cells and harming healthy tissues. Dose-finding studies in humans look for the “Goldilocks” zone—enough to disrupt cancer without catastrophic collateral damage. Strategies to cut toxicity range from tweaking the molecule for better selectivity, encapsulating it in nanoparticles for targeted delivery, and pairing it with drugs that protect bone marrow. Researchers regularly report both hurdles and hope: the molecule overcomes drug resistance, but pushing the therapeutic window wider—and making the treatment less punishing—remains a top priority.
Epothilone A and its chemical siblings still draw interest from across the scientific world. Drug discovery programs experiment with next-generation analogues boasting improved oral bioavailability and tailored delivery strategies. Immunotherapies and combination treatments perk up outcomes in drug-resistant cancers, making this class of molecules an essential tool. Synthetic chemists refine fermentation and total synthesis routes, bringing down costs and opening access to new analogues faster than ever before. Researchers continue studying how these molecules interact with microtubule dynamics in brain cells—hints point toward therapies for Alzheimer’s and other neurodegenerative diseases. Big questions remain about long-term safety, the best targets for treatment, and how to sidestep immune system reactions, but there’s little doubt that this molecule—born in an African river bed and propelled by decades of tireless innovation—remains central to the future of oncological science.
Epothilone A comes from a type of soil bacteria called Sorangium cellulosum. Scientists stumbled on it by accident, hunting for natural substances that could help in the battle against cancer. The story of a compound like this doesn’t usually make headlines, but those who spend time in medical labs and hospitals start to care a lot about what these molecules can do.
Epothilone A looks simple under a microscope, but its actions are complicated. It gets compared to taxol, a drug used to treat breast and ovarian cancers. Both attach to the tiny highways inside our cells—microtubules—and bring them to a standstill. A cell that can’t divide, can’t spread cancer.
Some tumors outsmart taxol by using proteins to pump it out before it does much harm. It’s like a housekeeper who throws your medicine away before you can even take it. Epothilone A sidesteps many of these tricks. It packs smaller luggage and sneaks deep into cancer cells, outfoxing resistance in some aggressive tumors. This trait caught the attention of researchers when they saw that many patients, especially those with tough-to-treat cancers, see new hope with drugs built on epothilone molecules.
Drug development never moves fast. Clinical trials for epothilone-based drugs, including ones related to Epothilone A, have been running for years. There are setbacks around every corner: unexpected side effects, costs, intense scrutiny from government regulators. Success comes in bits, not waves.
I’ve met people in clinical trials who sign up because regular treatments stopped working or made life unbearable. They’ll try something new, even with the uncertainty. For some patients, these epothilone drugs have held back disease longer than anyone expected, especially in breast and prostate cancer. Most of the drugs approved for real-world use come from Epothilone B, but A helps pave the way for new ideas, new combinations, and fresh starts in the lab.
Research goes beyond what we see in current headlines. Scientists noticed that epothilones also affect nerve cells and have been testing possibilities for diseases like Alzheimer’s. In mouse models, the drugs help protect nerve cells and control the tangle of fibers linked to memory loss. It’s early, and animal studies don’t always turn into cures for people, but this is how every breakthrough starts.
Turning a soil-borne molecule into medicine is like fixing a car with tools built for a spaceship. Mistakes happen, and sometimes the machine still breaks down. But stories from hospital halls remind us of the stakes. People want more time with family, another chance to see a sunrise. Epothilone A doesn’t hand out guarantees, but it sparks ideas, and in the world of medicine, ideas keep doors open.
Finding new uses, reducing side effects, and turning experimental treatments into real options takes effort across many fields: chemistry, oncology, nursing, and patient care. Sharing data, keeping patients informed, and building trust let us make steady progress. In my work, one truth stands out—real advances depend on the stubborn optimism of researchers and patients. Epothilone A shows the value of digging in the dirt, looking for gold, and believing that tiny things can change lives.
Epothilone A belongs to a group of natural compounds first discovered in myxobacteria, tiny organisms found in soil. Unlike many cancer drugs that have roots stretching back decades, epothilones gained notice much more recently. They drew scientists’ eyes for one reason: a knack for interfering with how cells divide, especially cancer cells.
Inside each cell, there’s a platform built from proteins called microtubules. These protein strands shape the cell, enable it to shuttle materials, and play a key role when cells pull apart and multiply. Cancer thrives on this process since tumor cells divide at breakneck speed.
Epothilone A interferes by binding directly to these microtubules. It forces the microtubules to stay stable when nature intends them to break apart—this stability stalls the division process. Cells, especially fast-growing cancer cells, struggle and often wither. Most healthy cells don’t get affected much since they don’t divide as rapidly as cancer cells. This difference helps explain why epothilones show promise against tumors even when older medications like taxanes lose effectiveness due to resistance.
Chemotherapy sometimes stops working. Tumors find sneaky ways to dodge the effects of standard treatments like paclitaxel (a taxane). Drug resistance remains one of the toughest hurdles for cancer specialists and patients alike. Epothilone A targets cancer in similar ways but sidesteps some of the common resistance problems seen with taxanes. For example, certain cancer cells pump out taxanes before the chemicals can do any harm. Epothilones don’t seem as vulnerable to this kind of pump.
Back in medical school, I remember a case where a patient’s breast cancer responded to epothilone-based therapy after everything else had failed. It left an impression—new tools can genuinely make a difference.
Even a promising drug comes with risks. By affecting cell division, epothilone A sometimes harms healthy cells—especially those in bone marrow, the gut, and hair follicles. Patients might experience infections, fatigue, or gastrointestinal troubles. Careful dosing and close monitoring make all the difference. Doctors weigh these risks against potential benefits, especially for patients who have exhausted other options.
Research keeps pushing forward. Some chemists have used what they know about epothilone A to create related compounds with even stronger effects or fewer side effects. These efforts sometimes lead to medicines that stand out in clinical trials.
Combining epothilone A with drugs that target other weaknesses in cancer cells could deliver stronger results. Trials look at ways to add immunotherapies or gene-targeted treatments to the mix. If one approach stumbles, the other may compensate.
Cancer touches nearly every family at some point. Watching new treatments give hope to people who’ve run out of options brings real meaning to research. Epothilone A’s direct attack on microtubules offers one more way to trip up cancer’s relentless growth. As long as researchers, doctors, and patients work together and share what they know, the field edges toward giving people a better shot at more years and better days.
Labs define results by how pure their chemicals are, especially with compounds like Epothilone A. Coming from soil bacteria, this small molecule often stands out in cancer research for its strong effect on microtubules. Impurities, even in trace amounts, can twist experiments or even derail months of work. Most scientists working with Epothilone A want purity levels above 98%. Anything less introduces uncertainty.
Those impurities don’t just water down results. They can trigger off-target cell effects or false positive signals in assays. Through my own time in a pharmacology lab, a small contaminant once threw off drug screening, only discovered weeks later using high-performance liquid chromatography (HPLC).
Academic labs and pharma companies won’t just trust labels. High purity claims mean little without numbers to back it up. HPLC and mass spectrometry tell the real story, exposing even the hidden leftovers from synthesis or degradation. Sequence confirmation by NMR matters too, especially since Epothilone A's activity ties directly to its exact structure. Published studies in Nature Chemical Biology and Journal of Medicinal Chemistry show that even 1% contamination can drop assay confidence.
People forget that pure chemicals are still vulnerable—Epothilone A wilts fast outside the right conditions. High temperatures promote hydrolysis, breaking sensitive bonds and leaving breakdown products behind. In graduate school, a poorly sealed sample left in a warm storeroom lost more than half its activity, costing me both results and grant opportunities.
Epothilone A belongs in a freezer—usually at or below -20°C—sealed tightly and kept dry. Light degrades it, so labs stick with amber vials or wrap glass in foil. Desiccators and dry argon or nitrogen can slow the slow creep of humidity into a vial. Vendors worth their price ship the compound on dry ice, with storage instructions right on the paperwork.
Simple mistakes defeat careful planning. In a 2019 study by Chen et al., improperly stored Epothilone A samples lost up to 40% of their initial potency in six months at room temperature. Those same vials, locked in -20°C freezers and kept away from light, showed almost zero loss. Stories like these remind us that proper storage isn’t about following rules—it’s about protecting months or years of investment and patient hope.
What keeps labs moving forward isn’t just smarter design; it’s respect for the basics. People who track their freezer temperatures and keep logs of when vials go in and out catch problems before they snowball. Digital monitors and alarms help too, but attention and habit make the biggest difference. Training new researchers to respect cold chain protocols, and regular audits of chemical stashes, prevent last-minute disasters.
Epothilone A plays too big a role in drug research to get careless. Between ever-tighter research budgets and intense competition, sticking with the highest purity and proper storage makes all the difference. The science improves, and so does the likelihood that good discoveries reach the people who need them most.
Epothilone A gets researchers talking. Known for its cancer-fighting promise, it’s been at the center of exciting lab work for years. Still, the stuff researchers use in Petri dishes isn't sitting in pharmacies or hospital shelves.
Cancer throws tough challenges at scientists. Chemotherapy has limits, and tough cancers like metastatic breast or ovarian disease often dodge current drugs. The search for better treatments pushes labs to hunt for compounds that work in new ways.
Epothilone A stands out because it flips the usual script. It slows down cell division, a critical weapon against tumors that can’t stop multiplying. Back in the late ‘90s, when researchers compared structures, they found Epothilone acts like a beefed-up cousin to paclitaxel (Taxol), but with the perk of working in cancers that resist Taxol.
Ask any scientist browsing catalogues for research chemicals—they only spot Epothilone A with warnings: "Research use only." You won’t see it listed as an FDA-approved drug, and doctors aren’t writing scripts for it. Drug regulators in the US, Europe, and elsewhere keep a close lid on compounds that haven’t survived the battery of clinical trials.
The only place Epothilone A moves around is between research labs or in companies designing clinical candidates. Even then, handling falls under heavy restrictions. Chemical suppliers demand buyers to show lab credentials, proof of legitimate research, and proper safety paperwork. No one at home can just order a vial online.
One hurdle: Safety. Early studies showed promise, but real-world use often brings complications—not all potent chemicals work out as drugs. Sometimes toxicity knocks candidates out of the race; sometimes issues like stability or cost make further steps impractical.
Epothilone B (ixabepilone), a close relative, made it into clinical use for a while, treating metastatic breast cancer. That success helped keep hope alive for other epothilones, but it also showed the tough road new cancer drugs face—each one has to prove both effective and safer than what’s already out there. For Epothilone A, the data just hasn't stacked up yet.
Advances in chemistry might change things. Better ways to modify chemical structure or deliver drugs could help dodge past safety pitfalls. Large-scale clinical studies cost big money though, so companies look for signs of clear advantage before they roll the dice. Collaboration between public research, pharma, and international agencies can speed things up, as seen with recent breakthroughs in other cancer treatments.
Transparency in research, sharing data on both positive and negative developments, matters more than ever. It helps avoid costly dead-ends and spot patterns that a single lab might miss. Funding from cancer foundations also plays a vital role, filling gaps in testing and pushing early candidates toward clinical trial readiness.
The line between "research only" and "approved for patients" isn’t just red tape—it means real questions about safety, effectiveness, and the ethics of delivering new treatments. While Epothilone A sits in the research column, the work continues. Hope for tough-to-treat cancers depends on relentless curiosity, but each step toward wider use needs thorough checks. No shortcut beats strong evidence, not in a field where the stakes involve lives.
Epothilone A stepped into cancer research over two decades ago as a promising alternative to paclitaxel. It showed strong microtubule-stabilizing activity even in resistant lines. Folks working in cell biology labs keep asking about the recommended concentration to use. I remember my first trial years back, hunting through published protocols, trying to avoid frying my cells. The numbers tossed around didn't always line up, and confusion could cost precious samples. The real answer: picking the “right” dosage depends on cell line, assay, and the outcome you expect, but some common ranges keep cropping up in peer-reviewed research.
Many studies in mammalian cell culture use Epothilone A in the low nanomolar zone—often from 1 nM up to 50 nM. For example, in a 2016 study published in Cancer Research, researchers treated A549 lung cancer cells with 5 nM, 10 nM, and 25 nM Epothilone A to examine tubulin acetylation and apoptosis. Toxicity shot up past 25 nM. Over at the biochemistry end, purified tubulin polymerization studies, like those in the Journal of Biological Chemistry, typically fall between 25 nM and 100 nM. Going above the established range often leads to off-target effects, muddied results, or cell death unrelated to the mechanism you want to study.
Experienced cell biologists recommend always running a dose-response curve. Cells vary widely in sensitivity—one batch of HeLa cells shriveled up at 2 nM, while another batch took 20 nM without missing a step. That’s why many labs take time to test across tenfold dilutions. It pays to keep old lab notebooks handy and check the concentrations that worked before.
Getting this tiny detail right matters. Mess up the concentration, and data sinks: too low misses effects, too high triggers non-specific toxicity. Irreproducible experiments waste time, money, and the trust of colleagues. Back in grad school, I learned the hard way—using a high concentration once led to cell death across all samples, even controls. Lost everything for the week. After that, I never skipped dose titration again. Over the past few years, the push for transparency in science means journals now look closely at dosing details, and some require full dose–response data before considering a paper.
Epothilone A’s purity, the vehicle (often DMSO), and storage method all influence outcomes. DMSO above 0.1% starts harming many cell types. Some batches from suppliers degrade if not frozen steadily, leading to lower apparent potency. Each time a new vial or batch arrives, repeat titration. Researchers who track lot numbers and document storage conditions tend to get repeatable results. Whenever people cut corners and skip these details, the data falls apart.
One approach saves headaches: record every detail. Note the exact concentration, cell line passage, media composition, batch number, and temperature. Share these methods in lab meetings or protocols. Swapping tips between labs makes it easier for newcomers to avoid rookie mistakes. Whenever I talk to early-career scientists, I remind them: control for every variable you can and respect others’ hard-won experience. Science never rewards the rushed shortcut.
Study design focusing on fundamentals—thorough titration, method transparency, routine controls—brings confidence and clarity. In cancer research, small molecules like Epothilone A can shape many outcomes, and good dosing practice pays off every time.
| Names | |
| Preferred IUPAC name | (1S,3S,7R,10R,11S,12Z,15S,16R)-3,7,11,15-tetramethyl-16-[(2S,3S)-2-methyl-3-hydroxyoxiran-2-yl]-1,5,8,19-tetraoxacycloicos-12-ene-2,9,18-trione |
| Other names |
Patupilone Utidelone |
| Pronunciation | /ˌɛp.əˈθaɪ.loʊn eɪ/ |
| Identifiers | |
| CAS Number | 159682-38-1 |
| Beilstein Reference | 131504 |
| ChEBI | CHEBI:49136 |
| ChEMBL | CHEMBL48536 |
| ChemSpider | 20892685 |
| DrugBank | DB12384 |
| ECHA InfoCard | ECHA InfoCard: 100.199.111 |
| EC Number | 3.1.1.228 |
| Gmelin Reference | 470557 |
| KEGG | C06507 |
| MeSH | D000077335 |
| PubChem CID | 6918153 |
| RTECS number | RQ3625000 |
| UNII | Q7C7H3C367 |
| UN number | UN1993 |
| Properties | |
| Chemical formula | C27H41NO6 |
| Molar mass | 493.684 g/mol |
| Appearance | White solid |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 2.8 |
| Vapor pressure | 6.98E-14 mmHg at 25°C |
| Acidity (pKa) | 2.84 |
| Basicity (pKb) | 2.69 |
| Dipole moment | 4.46 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 372.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -887.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8357.8 kJ/mol |
| Pharmacology | |
| ATC code | V10AX06 |
| Hazards | |
| Main hazards | Causes skin and eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | CC1CC2C(C(=O)NC(C=CC(CO)CC3CC(=O)NC3=O)=C2CO)OC1 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332 |
| Precautionary statements | P261-P264-P271-P272-P273-P280-P302+P352-P305+P351+P338-P333+P313-P337+P313-P362+P364 |
| NFPA 704 (fire diamond) | 1-2-1-🛢️ |
| Flash point | Flash point: 11.1 ± 18.7 °C |
| Lethal dose or concentration | LD50 (mouse, intravenous): 108 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | 5 μg/m³ |
| REL (Recommended) | 10 mM in DMSO |
| Related compounds | |
| Related compounds |
Epothilone B Epothilone C Epothilone D Epothilone E Epothilone F Epothilone N |
